Verve snags $60M from Lilly to tackle Lp(a) with one-time gene editing

Kyle LaHucik

Biotech Correspondent

Eli Lilly has tapped another gene editing partner, this time looking to go after a large patient population in the cardiovascular space with the help …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Verve snags $60M from Lilly to tackle Lp(a) with one-time gene editing

Kyle LaHucik

Biotech Correspondent

Sign up to read this article for free.

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Trump asks 'very tough hombre' Dr. Oz to lead MFN talks

Endpoints 100 biotech survey: Welcome to the summer of biotech’s discontent

Updated: Trump administration reveals 'most favored nation' drug price country targets

About 5% of CBER and CDER left after FDA staff cuts, analysis finds

US warns drugmakers against misrepresenting cost of imported products

Does your supply chain hold up under pressure for high-risk temperature-critical shipments?

Verve snags $60M from Lil­ly to tack­le Lp(a) with one-time gene edit­ing

Biotech Correspondent

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Verve snags $60M from Lilly to tackle Lp(a) with one-time gene editing